Month: February 2025

MIAMI, Feb. 10, 2025 (GLOBE NEWSWIRE) — PennantPark Investment Corporation (NYSE: PNNT) announced today its financial results for the first quarter ended December 31, 2024. HIGHLIGHTS Quarter ended December 31, 2024 (unaudited)($ in millions, except per share amounts) Assets and Liabilities:          Investment portfolio (1)       $ 1,298.1  Net assets       $ 494.3  GAAP net asset value per share       $ 7.57  Quarterly increase in GAAP net asset value per share         0.1 %Adjusted net asset value per share (2)       $ 7.57  Quarterly increase in adjusted net asset value per share (2)         0.1 %           Credit Facility       $ 460.0  2026 Notes       $ 148.8  2026-2 Notes       $ 163.3  Regulatory debt to equity       1.58x  Weighted average yield on debt investments         12.0 %           Operating...

Company delivers 96th consecutive quarter of topline growth Fourth quarter 2024 revenue grew 18% and recurring revenue grew 19% from the fourth quarter of 2023 MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) — SPS Commerce, Inc. (NASDAQ: SPSC), a leader in retail supply chain cloud services, today announced financial results for the fourth quarter and year ended December 31, 2024. Financial Highlights Fourth Quarter 2024 Financial HighlightsRevenue was $170.9 million in the fourth quarter of 2024, compared to $145.0 million in the fourth quarter of 2023, reflecting 18% growth. Recurring revenue grew 19% from the fourth quarter of 2023. Net income was $17.6 million or $0.46 per diluted share, compared to net income of $19.0 million or $0.51 per diluted share in the fourth quarter of 2023. Non-GAAP income per diluted share was $0.89,...

ARLINGTON, Va., Feb. 10, 2025 (GLOBE NEWSWIRE) — Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its results for the three months ended December 31, 2024. Financial Highlights for Fiscal Quarter ended December 31, 2024Revenue of approximately $186.8 million, which represents a decrease of approximately 49% from the same quarter last year, primarily driven by the pronounced backend nature of expected revenue for full year 2025 compared to the revenue distribution seen in full year 2024. GAAP gross profit margin improved to approximately 11.4%, compared to approximately 10.0% for the same quarter last year. Adjusted gross profit margin1 improved to approximately 12.5%, compared to...

DELRAY BEACH, Fla., Feb. 10, 2025 (GLOBE NEWSWIRE) — PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its third quarter ended December 31, 2024. Third Quarter Fiscal 2025 Financial HighlightsNet sales of $53.0 million.Gross margin rate of 28.1%, an increase of 80 basis points compared to the prior year period.Adjusted EBITDA of $2.0 million compared to Adjusted EBITDA of $0.9 million in the prior year period.Continued progress on key initiatives supporting the transformation of the business.“In just nine months, we have made significant strides in our transformation journey, and I am pleased to report that we have delivered meaningful progress across our strategic priorities. Our focused execution is already yielding results, validating our direction...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress. “In our second fiscal quarter we further strengthened our leadership with key Board appointments, reinforcing our commitment to innovation and execution as we work to develop next-generation therapeutics,” said CEO and Chief Scientific Officer Dr. Martin Brenner, Ph.D. “Following more recent developments, we also want to highlight the significant strides we have made in advancing our preclinical pipeline with the in-licensing of potentially best-in-class IBIO-600, the notable discovery of a novel Activin E antibody, and the launch of a bispecific antibody program targeting myostatin/activin A. We are excited by the momentum we have built...

Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH® in Europe and Market Authorization in Australia; international shipments to commence later this year Conference call at 4:30 p.m. ET today, February 10th GARDEN CITY, New York, Feb. 10, 2025 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced its financial results for the fiscal third quarter ended December 31, 2024, and provided a corporate update. “Our commercial team continues to make significant progress as we expand the number of U.S. hospitals utilizing LungFit PH. While this is the culmination...

MIAMI, Feb. 10, 2025 (GLOBE NEWSWIRE) — PennantPark Floating Rate Capital Ltd. (NYSE: PFLT) announced today its financial results for the first quarter ended December 31, 2024. HIGHLIGHTSQuarter ended December 31, 2024 (Unaudited)($ in millions, except per share amounts)Assets and Liabilities:      Investment portfolio (1)   $ 2,193.9  Net assets   $ 962.7  GAAP net asset value per share   $ 11.34  Quarterly increase in GAAP net asset value per share     0.3 %Adjusted net asset value per share (2)   $ 11.34  Quarterly increase in adjusted net asset value per share (2)     0.3 %       Credit Facility   $ 608.8  2036 Asset-Backed Debt   $ 284.2  2036-R Asset Backed Debt   $ 265.3  2026 Notes   $ 184.0  Regulatory debt to equity   1.40x  Weighted average yield on debt investments at quarter-end     10.6 %       Operating...

Record quarterly revenue of $141.1 million, up 25% QoQ and up 179% YoY Fiscal 2024 record revenue of $396.3 million, up 242% versus the prior year Ramping across diverse set of customers and platforms with four product families in fiscal 2025SANTA CLARA, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) — Astera Labs, Inc. (Nasdaq: ALAB), a global leader in semiconductor-based connectivity solutions for cloud and AI infrastructure, today announced preliminary financial results for the fourth quarter and full fiscal year 2024, ended December 31, 2024. “Astera Labs delivered strong Q4 results, with revenue growing 25% versus the previous quarter, and capped off a stellar 2024 with 242% revenue growth year-over-year,” said Jitendra Mohan, Astera Labs’ Chief Executive Officer. “The revenue growth in 2024 was largely driven by Aries PCIe Retimer...

Inspire Reports Year-over-Year Revenue Growth of 25% and Earnings per Share Growth of 135% for the Fourth Quarter 2024 MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter and year ended December 31, 2024. Recent Business Highlights and Full Year 2025 GuidanceGenerated revenue of $239.7 million for the fourth quarter of 2024, a 25% increase over the same quarter last year, and revenue of $802.8 million for full year 2024, a 28% increase over full year 2023 Achieved gross margin of 85.0% for the fourth quarter of 2024 Reported net income of $35.2 million and diluted net...